Events & conferences in the Life Sciences industry
Below you find a list of upcoming events in the Life Sciences industry. We will be attending all events which are flagged with the Biotechgate / Venture Valuation logo.
If you are participating the conference and want to learn more, please contact us to schedule a meeting ››
BIOSPAIN is the largest biotech event organized by a national bioindustry association in Europe and one of the largest in the world by the number of one-to-one meetings and companies participating. 34% of our delegates came from outside of Spain. This year, BIOSPAIN goes back to Barcelona, the main biotech cluster in Spain and one of the most dynamic cities in the world. The event will take place in Pavilion 1 – Fira de Barcelona – Montjuïc. It stands in a superb location in the city center, easily accessible from the airport and well-connected to the public transport network. It is located in Montjuïc Park, an area of cultural and historical interest thanks to its museums and theatres and it also features some of the main tourist attractions in Barcelona.
Representatives from Venture Valuation and Biotechgate will participate in BioSpain 2023
New York City USA
BioFuture is where relentless therapeutic pioneers, innovators, and investors gather to assess and shape the future of healthcare and digital health. Participate in candid, unfiltered discussions. At this year’s summit, we’ll explore the exciting mashup between rapidly evolving fields including biopharma, digital medicine, big data, AI, healthcare systems, payors, and more. The coming decade will dramatically accelerate the transformation of the healthcare ecosystem. Be part of the discussions that will shape and transform the future of healthcare.
Representatives from Venture Valuation and Biotechgate will participate in BioFuture
Featuring a twinned exhibition, seminars, and a large-scale partnering platform expected to bring together over 900 companies seeking to forge new partnerships, BioJapan and Regenerative Medicine Japan attract a wide range of organizations from Japan and abroad every year. Participants in BioJapan focus on drug discovery, licensing, and R&D, whereas Regenerative Medicine Japan is a hub for all sorts of organizations working in the rapidly expanding field of Regenerative Medicine. Besides a great number of universities, research organizations, and biotechs, almost every top pharma in Japan participates yearly in BioJapan’s partnering, making the event is well-poised as a venue for discovering new alliances with Japanese organizations.
Representatives from Venture Valuation and Biotechgate will participate in BioJapan
Australia's premier life sciences investment conference, AusBioInvest, is designed to drive investment outcomes and foster collaboration in life sciences and medical research. This flagship national conference offers the opportunity for companies to pitch to an audience of investors, including venture capital, private equity, high net worth individuals, research analysts and brokers, industry executives and major global stakeholders. The programme also features keynote presentations and panel discussions from investment specialists on topics including industry trends and updates from both domestic and global markets.
Representatives from Venture Valuation and Biotechgate will participate in AusBioInvest 2023
AusBiotech is Australia’s annual flagship industry conference and will continue to advance the biotech community with local and international industry leaders building relationships and having the opportunity to recharge, re-energise and refresh. Last year’s programme saw more than 1,000 delegates and over 150 speakers and chairs, as we reflected on what our sector achieved and networked face-to-face. AusBiotech 2023 will be held at the Brisbane Convention & Exhibition Centre from Wednesday 1 November to Friday 3 November 2023.
Representatives from Venture Valuation and Biotechgate will participate in AusBiotech 2023
BIO-Europe® event is the largest biotechnology partnering conference held in Europe. Over 4,000 global decision makers from biotechnology, pharma and finance annually attend BIO-Europe to identify new business opportunities and develop strategic relationships. Business development executives and dealmakers consider BIO-Europe a must-attend event and an effective business strategy enabling them to meet and present to numerous potential partners. BIO-Europe features the industry’s most advanced web-based partnering system enabling delegates from all parts of the biotechnology value chain to quickly identify, engage and enter into strategic relationships that drive their business successfully forward. BIO-Europe's world-class workshops, panels and active exhibition along with thousands of prescheduled one-to-one meetings make this event an unrivaled forum for companies across the biotech value chain to meet and do business.
Representatives from Venture Valuation and Biotechgate will participate in BIO-Europe® 2023
Biotechgate Digital Partnering November 2023
Biotechgate Digital Partnering is a virtual conference designed to support the business development of Biotech, Medtech and Pharma companies. Join five days of digital partnering and establish new global connections thanks to pre-arranged one-on-one Zoom meetings, along with informal networking events and workshops.
Representatives from Venture Valuation and Biotechgate will participate in Biotechgate Digital Partnering November 2023
Pharma-Biotech Product & Company Valuation with Dr. P Frei
An Introductory Course: Understand the valuation concepts and techniques that are commonly applied in the pharma and biotech world – Know how to assess and calculate the value of a biotech company – Learn how to calculate the value of a pharmaceutical in development and how to structure a licensing deal.
Representatives from Venture Valuation and Biotechgate will participate in Pharma-Biotech Product & Company Valuation with Dr. P Frei
Upcoming Life Sciences Events
- September 2023
- Barcelona: BioSpain 2023
- October 2023
- New York City: BioFuture
Latest company news
BioCity Signs Collaboration Agreement with AstraZeneca on BC3402, a monoclonal antibody targeting anti-TIM-3, in Combination with IMFINZI (durvalumab) for the Treatment of Advanced Hepatocellular Carcinoma in China